Multisite Controlled Trial of Cocaine Vaccine (TA-CD)
A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Clinical Efficacy, Safety, and Immunogenicity of a Human Cocaine Vaccine (TA-CD) in the Treatment of Cocaine Dependence
Sponsor: Baylor College of Medicine
Listed as NCT00969878, this PHASE2 trial focuses on Cocaine Dependence and remains completed. Sponsored by Baylor College of Medicine, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Celtic Pharma Development Services
- Columbia University
- Johns Hopkins University
- National Institute on Drug Abuse (NIDA)
- US Department of Veterans Affairs Cooperative Studies Program
- University of Cincinnati
- University of Pennsylvania
- VA Maryland Health Care System
- VA New York Harbor Healthcare System
For direct contact, visit the study record on ClinicalTrials.gov .